Our data showed that serum and urine levels of KIM-1 peaked at the acute phase but decreased gradually afterward, while NGAL increased continuously from the initiation of AKI to the chronic phase of the disease, indicating NGAL might be a better biomarker than KIM-1 in monitoring progression of AKI to CKD. The gene discussed is LCN2; the disease is chronic kidney disease.